- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00028873
R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
An EORTC-IDBBC/ECSG Phase II Study Evaluating The Role Of The Multi-Drug Resistance (MDR) Reversor, R101933, In Patients With Taxane Refractory Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining R101933 with paclitaxel or docetaxel may reduce resistance to the drug and allow the tumor cells to be killed.
PURPOSE: Phase II trial to study the effectiveness of combining R101933 with either paclitaxel or docetaxel in treating patients who have metastatic breast cancer that has not responded to previous chemotherapy.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
- Determine the activity of R101933 in combination with paclitaxel or docetaxel in terms of response to treatment and level of clinical benefit in patients with taxane-refractory metastatic breast cancer.
- Determine the safety of this regimen in these patients.
- Determine the acute side effects in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive R101933 IV over 1 hour immediately followed by paclitaxel IV over 3 hours or docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity. Patients who have no disease progression after 7 courses may continue with treatment at the investigator's discretion.
Patients are followed every 6 weeks until disease progression.
PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
DISEASE CHARACTERISTICS:
- Histologically confirmed metastatic breast cancer
- Received at least 2 prior courses of paclitaxel-based chemotherapy at doses between 175-200 mg/m^2 (given over 3 hours every 3 weeks) or docetaxel-based chemotherapy at doses between 75-100 mg/m^2 (given over 1 hour every 3 weeks) as most recent anticancer therapy
Evidence of disease resistance
- Progressive disease as best response OR
- Transient response or disease stabilization followed by progression during taxane-based treatment
- Disease progression on a combination of a taxane and another cytotoxic agent allowed
Unidimensionally measurable disease
- At least 1 target lesion that clearly progressed or developed during prior taxane therapy
- Lesions stable or responsive to prior taxane therapy are not considered target lesions
- Lesions that have been irradiated within the past 3 months are not considered target lesions unless they have clearly progressed or appeared since radiotherapy
- No bone metastases as only site of measurable disease
- No rapidly progressive visceral metastases
- No symptomatic CNS metastases
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Sex:
- Not specified
Menopausal status:
- Not specified
Performance status:
- WHO 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- Transaminases no greater than 2.5 times ULN (5 times ULN if liver metastases present)
Renal:
- Creatinine no greater than 1.5 times ULN
- Calcium normal
Cardiovascular:
- LVEF normal by echocardiogram (ECG) or MUGA scan
- QTc less than 450 sec on baseline ECG
- No prior clinically significant arrhythmias requiring treatment
- No cardiac infarction
- No atrial ventricular enlargement or hypertrophy
Other:
- No prior toxicity to paclitaxel that would preclude study dose and schedule
- Sodium, potassium, chloride, and bicarbonate normal
- No pre-existing neuropathy greater than grade 2
- No other prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix, contralateral breast cancer, or nonmelanoma skin cancer or cancer that has been in remission for more than 5 years
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No concurrent anticancer biologic agents
Chemotherapy:
- See Disease Characteristics
- No more than 8 weeks since last course of prior taxane-based chemotherapy
- No more than 2 prior chemotherapy regimens for metastatic breast cancer
- No other concurrent anticancer chemotherapy
Endocrine therapy:
- No concurrent anticancer hormonal therapy
Radiotherapy:
- See Disease Characteristics
- No concurrent radiotherapy
Surgery:
- Not specified
Other:
- No prior multi-drug resistance inhibitor
- No new anticancer therapy initiation since last course of prior taxane-based chemotherapy
- No concurrent angiotensin converting enzyme inhibitor and/or drugs that may prolong the QTc interval
- No other concurrent anticancer therapy
- Concurrent bisphosphonates for treatment and prevention of bony metastases allowed provided drugs were initiated prior to study (treatment of hypercalcemia due to malignancy allowed regardless of time of initiation)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
Colaboradores e Investigadores
Investigadores
- Cadeira de estudo: Pierre Fumoleau, MD, PhD, Centre Georges Francois Leclerc
- Cadeira de estudo: Bernardo L. Rapoport, MD, MMed(IntMed), Medical Oncology Centre of Rosebank
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- EORTC-10003-16004
- EORTC-16004
- ECSG-EORTC-16004
- IDBBC-10003
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer de mama
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
-
Ohio State University Comprehensive Cancer CenterConcluídoSobrevivente de cancerEstados Unidos
Ensaios clínicos em docetaxel
-
Nereus Pharmaceuticals, Inc.ConcluídoCâncerEstados Unidos, Austrália, Índia, Chile, Brasil, Argentina
-
Optimal Health ResearchConcluídoCâncer de mama | Câncer de pulmão | Câncer de próstataEstados Unidos
-
Tianjin Medical University Cancer Institute and...Recrutamento
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaConcluídoCâncer de Pulmão de Células Não Pequenas (NSCLC)China
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical Center e outros colaboradoresDesconhecidoCâncer de intestinoRepublica da Coréia
-
Arog Pharmaceuticals, Inc.RetiradoCarcinoma pulmonar de células não pequenas
-
Zhuhai Beihai Biotech Co., LtdConcluídoTumores Sólidos | Bioequivalência | DocetaxelÍndia
-
SanofiConcluídoNeoplasias PulmonaresFrança, Holanda, Espanha, Peru, Bélgica, Finlândia, Itália, Reino Unido
-
SanofiConcluídoNeoplasias de Cabeça e PescoçoFrança
-
Fudan UniversityAinda não está recrutandoEnvafolimabe mais docetaxel em combinação com ou sem trilaciclibe versus docetaxel em NSCLC avançadoCâncer Avançado de Pulmão de Células Não Pequenas